The Critical Path for Parkinson's Consortium Approach to Developing Consensus Recommendations for Neuroimaging Biomarkers Appropriate for use in Parkinson's Disease Drug Development

被引：0
|
作者：
Muller, M.
Comley, R.
Eberling, J.
Kazmi, H.
Kustermann, T.
Maguire, P.
Marek, K.
McGinnity, C.
Minchik, M.
Parker, C.
Passamonti, L.
Rousset, O.
Russell, D.
Salinas, C.
Seibyl, J.
Sivakumaran, S.
Stoessl, J.
Strafella, A.
Tosun-Turgut, D.
Wang, Y.
Stephenson, D.
Pagano, G.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1590
引用
收藏
页码：S701 / S701
页数：1
相关论文
共 50 条
  • [41] The critical path for Parkinson's consortium: Understanding motor disase progression through quantitative medicine
    Romero, K.
    Conrado, D.
    Corrigan, B.
    Tsai, K.
    Ahamadi, M.
    Macha, S.
    Sinha, V.
    Watson, I.
    Bani, M.
    Muglia, P.
    Kern, V.
    Williams-Gray, C.
    Grosset, D.
    Hu, M.
    Burn, D.
    Lawson, R.
    Marek, K.
    Roach, A.
    Stephenson, D.
    Nicholas, T.
    MOVEMENT DISORDERS, 2017, 32
  • [42] A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice
    Pagonabarraga, Javier
    Arbelo, Jose Matias
    Grandas, Francisco
    Luquin, Maria-Rosario
    Martin, Pablo Martinez
    Rodriguez-Oroz, Mari Cruz
    Valldeoriola, Francesc
    Kulisevsky, Jaime
    BRAIN SCIENCES, 2020, 10 (03)
  • [43] Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal
    Jost, Wolfgang H.
    TOXINS, 2021, 13 (02)
  • [44] Inappropriate Antidopaminergic Drug Use in Parkinson's Disease Inpatients
    Domingo-Echaburu, Saioa
    Lertxundi, Unax
    Gonzalo-Olazabal, Elena
    Peral-Aguirregoitia, Javier
    Pena-Bandres, Inaki
    CURRENT DRUG THERAPY, 2012, 7 (03) : 164 - 169
  • [45] Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
    Chen, HL
    Jacobs, E
    Schwarzschild, MA
    McCullough, ML
    Calle, EE
    Thun, MJ
    Ascherio, A
    ANNALS OF NEUROLOGY, 2005, 58 (06) : 963 - 967
  • [46] Developing MRI-Based Biomarkers for Early Diagnosis of Parkinson's Disease
    Andersen, A.
    Hardy, P.
    Grondin, R.
    Gerhardt, G.
    Zhang, Z.
    CELL TRANSPLANTATION, 2011, 20 (04) : 545 - 545
  • [47] Drug insight: new drugs in development for Parkinson's disease
    Colosimo, Carlo
    Fabbrini, Giovanni
    Berardelli, Alfredo
    NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (11): : 600 - 610
  • [48] A scoping review of drug exposures and the development of Parkinson's disease
    Itaya, Takahiro
    Hallam, Brendan
    Orlu, Mine
    Schrag, Anette
    Petersen, Irene
    Walters, Kate
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 492 - 493
  • [49] A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement
    de Roos, Paul
    Bloem, Bastiaan R.
    Kelley, Thomas A.
    Antonini, Angelo
    Dodel, Richard
    Hagell, Peter
    Marras, Connie
    Martinez-Martin, Pablo
    Mehta, Shyamal H.
    Odin, Per
    Chaudhuri, Kallol Ray
    Weintraub, Daniel
    Wilson, Bil
    Uitti, Ryan J.
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (03) : 533 - 543
  • [50] Advances in Drug Development for Parkinson's Disease: Present Status
    Reddy, Dibbanti Harikrishna
    Misra, Shubham
    Medhi, Bikash
    PHARMACOLOGY, 2014, 93 (5-6) : 260 - 271
12345